
Federal Election 2025: Anthony Albanese sets the date for May 3
Australians will head to the polls in five weeks, with Prime Minister Anthony Albanese officially calling the 2025 federal election
Australians will head to the polls in five weeks, with Prime Minister Anthony Albanese officially calling the 2025 federal election
Political fallout is mounting as some Republicans are breaking with the White House on the severity of the leak.
Melissa O’Leary, CSO at Fortalice Solutions, discussed cybersecurity concerns after security leaders inadvertently added a journalist to a Signal group chat.
Manna has raised $30 million to fund an ambitious expansion, taking on well-funded competitors like Amazon, Alphabet and unicorn Zipline. It could be first to scale a mass drone delivery operation.
The divestment comes after WiseTech appointed its founder Richard White as executive chairman last month, enabling the tycoon to take back control of the company four months after quitting as CEO following a series of damaging media reports.
Mark Bouris has built empires, mentored entrepreneurs, and sparked deep conversations through his podcast Straight Talk. In this episode of Drive with a CEO, he joins Forbes Australia Editor-in-Chief Sarah O’Carroll in the Range Rover Sport to talk about discipline, curiosity, his parents’ influence, and what drives him at 70.
From tax cuts to tobacco revenue, here’s who came out ahead – and who didn’t in – in Treasurer Jim Chalmers’ pre-election federal budget pitch.
With a looming federal election and a decade of deficits forecast, Treasurer Jim Chalmers has framed this year’s budget as a “platform for prosperity” – balancing modest cost-of-living relief with broader ambitions to build economic resilience.
Wojcicki said she intends to become an outside bidder to acquire the company’s assets after her earlier efforts to take 23andMe private failed.
Australia’s visionary eye-health company Opthea, which raised almost $1 billion to bring its eye injection to market, is fighting for survival today after the failure of its first Phase-3 trial.